Nonclinical Validation of the NexPTM Half-Life Extension Platform Using Human Growth Hormone as a Model Therapeutic Protein
Abstract NexP™ is a proprietary carrier platform engineered from human alpha-1 antitrypsin (A1AT) to extend the systemic exposure of therapeutic proteins while retaining biological activity. The NexP™ scaffold incorporates an additional N-linked glycosylation site and a mutation in the reactive center loop designed to reduce its intrinsic protease inhibitory activity. Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological performance, safety profile, and developability of the NexP™ platform. ALT-P1, a long-acting hGH candidate, containing NexP™ at its C-terminus of hGH, was produced in mammalian cells and purified by a series of column chromatography steps. The purified protein was characterized Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological properties, nonclinical safety, and developability of this platform. ALT-P1, an hGH fusion protein containing NexP™ at its C-terminus, was produced in mammalian cells and purified using chromatographic methods. ALT-P1 was characterized by physicochemical analyses, including SDS-PAGE, isoelectric focusing, size-exclusion chromatography, N-linked glycan profiling, and circular dichroism (CD) spectroscopy. Binding affinity for the human growth hormone receptor and in vitro activity were further assessed by receptor-binding, MTS-based cell proliferation and luciferase reporter assays. Pharmacokinetic, pharmacodynamic, and toxicological profiles were evaluated in Sprague-Dawley rats and cynomolgus monkeys. Systemic exposure to ALT-P1 increased with increasing subcutaneous doses in rats, and pharmacokinetic studies demonstrated sustained systemic exposure in both species. ALT-P1 increased serum insulin-like growth factor I (IGF-1) levels in cynomolgus monkeys and promoted body weight gain and tibial growth in hypophysectomized rats. In a 26 week repeated-dose toxicity study in cynomolgus monkeys, ALT-P1 was generally well tolerated, with a no-observed-adverse-effect level (NOAEL) of 20 mg/kg, the highest dose tested. A GMP-manufactured clinical batch maintained its quality attributes and biological potency during long-term storage. Collectively, these findings support the further development of ALT-P1 as a long-acting hGH candidate and suggest the potential applicability of NexP™ as a half-life-extension platform for other biologic therapeutics.
Authors
- Changkwon Song
- Sang Mee Lee (ORCID: https://orcid.org/0000-0001-9425-8077)
- Hye-Shin Chung
- Jeong Soo Cho
- Sun-Ah You
- Yi Jin Song
- Ji-Sun Kim
- Jinhee Lee (ORCID: https://orcid.org/0000-0001-7172-0409)
- Jaehyeong Ko (ORCID: https://orcid.org/0009-0008-7416-5269)
- Sang Hee Lee
- Kyuwan Kim
- Kibum Park
- Tae-Yon Chun
- Ji Eun Hong
- Minsoo Byun
- Soon Jae Park
Institutions
- Alteogen (South Korea) (KR)
Publication Details
- Journal
- Molecular Pharmaceutics
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1021/acs.molpharmaceut.6c01038
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Korea Evaluation Institute of Industrial Technology